Abstract: Alendronate is widely used in the treatment of osteoporosis and other bone diseases. Although it is considered a well-tolerated drug, there are numerous reports of adverse effects on the mucosa in the upper aerodigestive tract, with oesophagitis as the most common complication. The strict regulations for the proper administration of the drug indicate that these side effects might well be the result of a direct, irritant mechanism on the upper aerodigestive tract. We present two clinical cases of patients who developed extensive palatal ulcers as a result of taking alendronate. We discuss possible mechanisms implicated in the production of the ulcers and some clinical factors of interest.
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Alendronate (Fosamax

A
) is a drug belonging to the diphosphonate family (4-amino-1-hydroxybutylidene 1,1-diphosphonate) that has recently been used in the treatment of osteoporosis (1) (2) (3) (4) . It has been demonstrated that this drug induces a progressive and significant increase in bone mineral density in women with osteoporosis (5) and with both hyperthyroidism and osteoporosis (6) . Alendronate has also proven to be effective in the treatment of glucocorticoidinduced osteoporosis (7) . On the other hand, the administration of this drug to patients with Paget's disease induced a noticeable reduction in the urinary excretion of hydroxiproline, followed by a fall in the serum activity of alkaline phosphatase and in bone turnover rates (8) .
The high prevalence of diseases in which alendronate has proven to be effective has led to its increasing use. Though it has been affirmed to be a well-tolerated drug (5, 9) , adverse side effects on the mucosa in the upper aerodigestive tract have been reported, with oesophagitis as the commonest complication (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . We describe two clinical cases in which extensive ulcers related to taking alendronate appeared on the oral mucosa. sults in each case. Diagnostic tests for HIV infection and syphilis were both negative. Complete haematological analyses only demonstrated the presence of a discrete anaemia (3,000,000 erythrocytes/ mm). The patient's previous medication was suspended and she was treated with deflazacort (30 mg/d/5 d) followed by clobetasol propionate at 0.05%πnystatin 100,000 UI/cc in orabase (3 applications a day using the prosthesis as a support). At the first checkup after 20 days (end of July, 1998) no change was observed in the lesion. She was told to continue with the local corticoid at the same rate and to take no other drug orally.
At the second check-up (beginning of September, 1998) no improvement in the lesion was observed. However, the patient reported that she had restarted treatment with alendronate. This drug was again suspended and she was told to continue with the local corticoid treatment. The patient was then monitored every 15 days. At the check-up on October 15, 1998 a minor improvement in the lesion was noted. The improvement in the ulcer was progressive until the almost complete disappearance of the lesion (January, 1999) ( (Fig. 2B) . From December, 1997, the alendronate treatment was suspended and the patient was treated with clobetasol propionate at 0.05%πnystatin (100,000 UI/cc) in orabase applied on the palate surface of the prosthesis and on a swab Alendronate-related oral mucosa ulcers placed on the tongue and lip lesions. At follow-up in January, 1998, an improvement was observed in the palate and lip lesions without any change in the tongue lesion. By April, 1998, all the lesions had disappeared (Fig. 3B ).
Discussion
Alendronate is widely used for treating osteoporosis and other bone diseases (1-4). Although it is deemed to be a well-tolerated drug (5, 9), there have been frequent reports of adverse effects on the mucosa in the upper aerodigestive tract, with oesophagitis as the commonest complication (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . The correct procedure is for the patient to take the medication with a full glass of water, avoiding any chewing or sucking of the tablet, and to maintain an upright posture for at least 30 minutes afterwards. All these preventive measures indicate that the adverse effects of alendronate on the upper aerodigestive mucosa may be the result of a direct irritant mechanism (25) .
Both of the patients described in the present report developed extensive ulcers on the palate and one of them also had ulcers on the tongue and lower lip. These lesions disappeared slowly after withdrawal of the drug. Another two case reports of mucosal ulcerations of the mouth have also been reported in the medical literature (23, 24) . Interestingly, the palatal ulcers reported were of considerable size and were similar to each another, with the same appear- ance as oral ulcers that arise from immunity disorder-related diseases, such as pemphigoid and lichen planus. The reports revealed that the response to corticoid treatment was poor and that the ulcers remitted slowly over long periods of time after withdrawal of the drug. This slowness of response had created diagnostic uncertainty in the two present cases, since drug-related oral ulcers normally remit more speedily after withdrawal of the medication causing the process. On the other hand, it is known that in skin allergic responses to drugs, healing can take many months.
It is difficult to categorically identify the mechanism by which alendronate produced the oral lesions in the clinical cases presented
here. It has been demonstrated that alendronate may cause gastric ulcers in rabbits through a direct irritant effect and that it increases the rate and the size of indomethacin-induced ulcers (25) . However, some clinical factors make it difficult to accept a direct irritant effect of the drug as the exclusive mechanism for the production of the oral ulcers in the cases described. Both patients used upper prostheses that they did not remove when taking the drug. Furthermore, although neither patient followed the correct administration procedure, one patient (case no. 1) suffered no ulcers on the back of her tongue or at any other location, despite keeping the pill on her tongue for a time before swallowing it. Moreover, both patients had taken alendronate for long periods of time (5 months and 1 year, respectively) before the appearance of the ulcers.
It is of interest to understand this phenomenon, since it may well create confusion in the diagnosis of conditions with similar symptoms.
